Accept Refuse

EUR-Lex Access to European Union law

This document is an excerpt from the EUR-Lex website

Document 32018R1480

Commission Regulation (EU) 2018/1480 of 4 October 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776 (Text with EEA relevance.)

C/2018/6348

OJ L 251, 5.10.2018, p. 1–12 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

In force

ELI: http://data.europa.eu/eli/reg/2018/1480/oj

5.10.2018   

EN

Official Journal of the European Union

L 251/1


COMMISSION REGULATION (EU) 2018/1480

of 4 October 2018

amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) and Article 53(1) thereof,

Whereas:

(1)

Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.

(2)

Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of the Agency (RAC), as well as on the comments received from the parties concerned, it is appropriate to introduce, update or delete harmonised classification and labelling of certain substances.

(3)

Council Directive 67/548/EEC (2) and Directive 1999/45/EC of the European Parliament and of the Council (3) were repealed with effect from 1 June 2015. As a result, Part 3 of Annex VI to Regulation (EC) No 1272/2008 was amended by Commission Regulation (EU) 2016/1179 (4) to remove Table 3.2. That amendment took effect on 1 June 2017. Annex VI to Regulation (EC) No 1272/2008 was further amended by Commission Regulation (EU) 2017/776 (5) to delete references to Table 3.2, to convert references to Table 3.1 into references to Table 3 and to delete references to the repealed Directives. Under Article 2(2) of Regulation (EU) 2017/776, the majority of those amendments were to apply from 1 June 2017, while the remaining amendments were stated to apply from 1 December 2018. However, due to an oversight, Article 2(2) failed to list two further amendments that should have applied from 1 June 2017, including in particular the amendment changing the name of the Table from ‘Table 3.1’ to ‘Table 3’. The second subparagraph of Article 2(2) of Regulation (EU) 2017/776 should therefore be corrected to include reference to those two amendments. This correction, although it has the effect of applying the two amendments retroactively, does not affect the rights and obligations of manufacturers, importers, downstream users or suppliers.

(4)

Regulation (EU) 2017/776 also amended Annex VI to Regulation (EC) No 1272/2008 to add harmonised ‘Acute Toxicity Estimate’ (ATE) values in Table 3.1 as part of the information relating to the classification and labelling of certain substances for the purposes of the classification of mixtures. The ATE introduced for nicotine was expressed in mg/kg. In order to clarify how mixtures containing nicotine should be classified, the ATE for the oral and the dermal routes for nicotine should instead be expressed in ‘mg/kg bw’ (6). The ATEs for three other substances, namely colecalciferol, 1,2-dihydroxybenzene and pinoxaden should also be expressed in the same way. In addition, in the title of the penultimate column of Table 3.1, a footnote should be added indicating what the abbreviation ‘mg/kg bw’ stands for.

(5)

The Annex to Commission Regulation (EU) 2018/669 (7) provides for the translation of the names of the substances included in Table 3.1 of Annex VI to Regulation (EC) No 1272/2008. As a consequence, the title of the second column of that Table, which currently refers to ‘international chemical identifications’, should be amended to take account of the fact that the ‘international chemical identifications’ will lose their international character once the Regulation providing for their translation in Annex VI becomes applicable. For the sake of consistency, this amendment should take effect when the translation of the names in Annex VI takes effect. The new title should reflect the terminology used in Article 18 of Regulation (EC) No 1272/2008.

(6)

Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks. That period of time will also be necessary to allow suppliers to adapt to and comply with other legislative obligations resulting from the new or updated harmonised classifications, such as those set out in Article 22(f) or Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (8), those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (9) or those set out in Article 44 of Regulation (EC) No 1107/2009 of the European Parliament and of the Council (10).

(7)

Regulation (EC) No 1272/2008 should therefore be amended accordingly.

(8)

In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow for new provisions to be applied at an earlier stage on a voluntary basis, suppliers should be allowed to apply the new and updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of those new or updated classifications.

(9)

The measures provided for in this Regulation are in accordance with the opinion of the Committee established by Article 133 of Regulation (EC) No 1907/2006,

HAS ADOPTED THIS REGULATION:

Article 1

Amendment to Regulation (EC) No 1272/2008

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2

Correction to Regulation (EU) 2017/776

In Regulation (EU) 2017/776, the second subparagraph of Article 2(2) is replaced by the following:

‘In the Annex, point (1), point (2) and points (a), (b) and (c) of point (3) shall apply from 1 June 2017.’

Article 3

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

Point (1) and point (a) of point (2) of the Annex shall apply from 1 December 2019.

Points (b), (c), (d) and (e) of point (2) of the Annex shall apply from 1 May 2020.

By way of derogation from the third paragraph of this Article, substances and mixtures may, before 1 May 2020, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 4 October 2018.

For the Commission

The President

Jean-Claude JUNCKER


(1)  OJ L 353, 31.12.2008, p. 1.

(2)  Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).

(3)  Directive 1999/45/EC of the European Parliament and of the Council of 31 May 1999 concerning the approximation of laws, regulations and administrative provisions of the Member States relating to the classification, packaging and labelling of dangerous preparations (OJ L 200, 30.7.1999, p. 1).

(4)  Commission Regulation (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (OJ L 195, 20.7.2016, p. 11).

(5)  Commission Regulation (EU) 2017/776 of 4 May 2017 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (OJ L 116, 5.5.2017, p. 1).

(6)  Body weight.

(7)  Commission Regulation (EU) 2018/669 of 16 April 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (OJ L 115, 4.5.2018, p. 1).

(8)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

(9)  Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).

(10)  Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC (OJ L 309, 24.11.2009, p. 1).


ANNEX

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1)

in Part 1, the heading of point 1.1.1.4 is replaced by the following:

Chemical name’;

(2)

in Part 3, Table 3.1 is amended as follows:

(a)

the title of the second column is replaced by the following: ‘Chemical name’;

(b)

the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*)

(*)

ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’;

(c)

the entry corresponding to index number 607-414-00-6 is deleted;

(d)

the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively:

Index No

Chemical name

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M-factors and ATEs

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

‘006-044-00-7

isoproturon (ISO);

3-(4-isopropylphenyl)-1,1-dimethylurea

251-835-4

34123-59-6

Carc. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H373 (blood)

H400

H410

GHS08

GHS09

Wng

H351

H373 (blood)

H410

 

M = 10

M = 10’

 

‘015-101-00-5

phosmet (ISO);

S-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate;

O,O-dimethyl-S-phthalimidomethyl phosphorodithioate

211-987-4

732-11-6

Repr. 2

Acute Tox. 4

Acute Tox. 3

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H361f

H332

H301

H370 (nervous system)

H400

H410

GHS08

GHS06

GHS09

Dgr

H361f

H332

H301

H370 (nervous system)

H410

 

M = 100

M = 100’

 

‘016-096-00-2

thifensulfuron-methyl (ISO);

methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate

79277-27-3

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

 

M = 100

M = 100’

 

‘017-011-00-1

sodium hypochlorite, solution … % Cl active

231-668-3

7681-52-9

Skin Corr. 1B

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H314

H318

H400

H410

GHS05

GHS09

Dgr

H314

H410

EUH031

M = 10

M = 1

EUH031:

C ≥ 5 %

B’

‘025-002-00-9

potassium permanganate

231-760-3

7722-64-7

Ox. Sol. 2

Repr. 2

Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1

H272

H361d

H302

H400

H410

GHS03

GHS08

GHS07

GHS09

Dgr

H272

H361d

H302

H410’

 

 

 

‘603-180-00-4

colecalciferol;

cholecalciferol;

vitamin D3

200-673-2

67-97-0

Acute Tox. 2 Acute Tox. 2 Acute Tox. 2

STOT RE 1

H330

H310

H300

H372

GHS06

GHS08

Dgr

H330

H310

H300

H372

 

 

inhalation:

ATE = 0,05 mg/L (dusts or mists)

 

dermal:

ATE = 50 mg/kg bw

 

oral:

ATE = 35 mg/kg bw

STOT RE 1; H372: C ≥ 3 %

STOT RE 2; H373: 0,3 % ≤ C < 3 %’

 

‘604-014-00-3

chlorocresol;

4-chloro-m-cresol;

4-chloro-3-methylphenol

200-431-6

59-50-7

Acute Tox. 4

Skin Corr. 1C

Eye Dam. 1

STOT SE 3

Skin Sens. 1B Aquatic Acute 1

Aquatic Chronic 3

H302

H314

H318

H335

H317

H400

H412

GHS07

GHS05

GHS09

Dgr

H302

H314

H335

H317

H410

 

M = 1’

 

‘604-016-00-4

1,2-dihydroxybenzene;

pyrocatechol

204-427-5

120-80-9

Carc. 1Β

Muta. 2

Acute Tox. 3

Acute Tox. 3

Skin Irrit. 2

Eye Irrit. 2

H350

H341

H311

H301

H315

H319

GHS08

GHS06

Dgr

H350

H341

H311

H301

H315

H319

 

 

oral:

ATE = 300 mg/kg bw

 

dermal:

ATE = 600 mg/kg bw’

 

‘604-090-00-8

4-tert-butylphenol

202-679-0

98-54-4

Repr. 2

Skin Irrit. 2

Eye Dam. 1

Aquatic Chronic 1

H361f

H315

H318

H410

GHS08

GHS05

GHS09

Dgr

H361f

H315

H318

H410

 

M = 1’

 

‘605-003-00-6

acetaldehyde;

ethanal

200-836-8

75-07-0

Flam. Liq. 1

Carc. 1B

Muta. 2

STOT SE 3

Eye Irrit. 2

H224

H350

H341

H335

H319

GHS02

GHS08

GHS07

Dgr

H224

H350

H341

H335

H319’

 

 

 

‘606-047-00-9

2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone

404-360-3

119313-12-1

Repr. 1B

Aquatic Acute 1

Aquatic Chronic 1

H360D

H400

H410

GHS08

GHS09

Dgr

H360D

H410’

 

 

 

‘607-096-00-9

maleic anhydride

203-571-6

108-31-6

Acute Tox. 4

STOT RE 1

Skin Corr. 1B

Eye Dam. 1

Resp. Sens. 1

Skin Sens. 1A

H302

H372 (respiratory system) (inhalation)

H314

H318

H334

H317

GHS07

GHS08

GHS05

Dgr

H302

H372 (respiratory system) (inhalation)

H314

H334

H317

EUH071

Skin Sens. 1A; H317: C ≥ 0,001 %’

 

‘607-103-00-5

succinic anhydride

203-570-0

108-30-5

Acute Tox. 4

Skin Corr. 1

Eye Dam. 1

Resp. Sens. 1

Skin Sens. 1

H302

H314

H318

H334

H317

GHS07

GHS05

GHS08

Dgr

H302

H314

H334

H317

EUH071’

 

 

‘607-113-00-X

isobutyl methacrylate

202-613-0

97-86-9

Flam. Liq. 3

STOT SE 3

Skin Irrit. 2

Skin Sens. 1B

H226

H335

H315

H317

GHS02

GHS07

Wng

H226

H335

H315

H317

 

 

D’

‘607-373-00-4

quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate

414-200-4

200509-41-7

Carc. 2

Repr. 2

Acute Tox. 4

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361fd

H302

H373

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361fd

H302

H373

H410

 

M = 1

M = 1’

 

‘613-167-00-5

reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)

55965-84-9

Acute Tox. 2

Acute Tox. 2

Acute Tox. 3

Skin Corr. 1C

Eye Dam. 1

Skin Sens. 1A Aquatic Acute 1

Aquatic Chronic 1

H330

H310

H301

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H310

H301

H314

H317

H410

EUH071

Skin Corr. 1C; H314: C ≥ 0,6 %

Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %

Eye Dam. 1; H318: C ≥ 0,6 %

Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %

Skin Sens. 1A; H317: C ≥ 0,0015 %

M = 100

M = 100

B’

‘613-205-00-0

propiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole

262-104-4

60207-90-1

Repr. 1B

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H302

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H360D

H302

H317

H410

 

M = 1

M = 1’

 

‘614-001-00-4

nicotine (ISO);

3-[(2S)-1-methylpyrrolidin-2-yl]pyridine

200-193-3

54-11-5

Acute Tox. 2

Acute Tox. 2

Acute Tox. 2

Aquatic Chronic 2

H330

H310

H300

H411

GHS06

GHS09

Dgr

H330

H310

H300

H411

 

 

inhalation:

ATE = 0,19 mg/L (dusts or mists)

 

dermal:

ATE = 70 mg/kg bw

 

oral:

ATE = 5 mg/kg bw’

 

(e)

the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1:

Index No

Chemical name

EC No

CAS No

Classification

Labelling

Specific Conc. Limits, M-factors and ATEs

Notes

Hazard Class and Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

‘604-094-00-X

isoeugenol; [1]

(E)-2-methoxy-4-(prop-1-enyl)phenol; [2]

(Z)-2-methoxy-4-(prop-1-enyl)phenol [3]

202-590-7 [1]

227-678-2 [2]

227-633-7 [3]

97-54-1 [1]

5932-68-3 [2]

5912-86-7 [3]

Skin Sens. 1A

H317

GHS07

Wng

H317

 

Skin Sens. 1A; H317: C ≥ 0,01 %’

 

‘607-724-00-1

2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin

240494-71-7

Acute Tox. 4

Acute Tox. 3

STOT SE 1

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H370 (nervous system)

H373

H400

H410

GHS06

GHS08

GHS09

Dgr

H332

H301

H370 (nervous system)

H373

H410

 

M = 100

M = 100’

 

‘607-725-00-7

isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene

65733-16-6

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

 

M = 1

M = 1’

 

‘607-726-00-2

pinoxaden (ISO);

8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate

243973-20-8

Repr. 2

Acute Tox. 4

Acute Tox. 4

Eye Irrit. 2

STOT SE 3

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 3

H361d

H332

H302

H319

H335

H317

H400

H412

GHS08

GHS07

GHS09

Wng

H361d

H332

H302

H319

H335

H317

H410

 

 

inhalation:

ATE = 4,63 mg/L (dusts or mists)

 

oral:

ATE = 500 mg/kg bw

M = 1’

 

‘607-727-00-8

tetramethrin (ISO);

(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate

231-711-6

7696-12-0

Carc. 2

Acute Tox. 4

STOT SE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H371 (nervous system) (inhalation)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H371 (nervous system) (inhalation)

H410

 

M = 100

M = 100’

 

‘607-728-00-3

(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate

214-619-0

1166-46-7

Carc. 2

Acute Tox. 4

STOT SE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H371 (nervous system) (inhalation)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H371 (nervous system) (inhalation)

H410

 

M = 100

M = 100’

 

‘607-729-00-9

mesosulfuron-methyl (ISO);

methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate;

208465-21-8

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

 

M = 100

M = 100’

 

‘607-730-00-4

spirodiclofen (ISO);

3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate

148477-71-8

Carc. 1B

Repr. 2

STOT RE 2

Skin Sens. 1B

Aquatic Chronic 1

H350

H361f

H373

H317

H410

GHS08

GHS07

GHS09

Dgr

H350

H361f

H373

H317

H410

 

M = 10’

 

‘607-731-00-X

sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium

218-953-8

2302-17-2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

 

M = 1

M = 1’

 

‘607-732-00-5

salicylic acid

200-712-3

69-72-7

Repr. 2

Acute Tox. 4

Eye Dam. 1

H361d

H302

H318

GHS08

GHS07

GHS05

Dgr

H361d

H302

H318’

 

 

 

‘608-068-00-9

flutianil (ISO);

(2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile

958647-10-4

Aquatic Chronic 1

H410

GHS09

Wng

H410

 

M = 100’

 

‘612-293-00-8

reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine

447-920-2

-

Repr. 2

Acute Tox. 4

Skin Corr. 1B

Eye Dam. 1

H361f

H302

H314

H318

GHS08

GHS07

GHS05

Dgr

H361f

H302

H314

EUH071’

 

 

‘613-326-00-9

2-methylisothiazol-3(2H)-one

220-239-6

2682-20-4

Acute Tox. 2

Acute Tox. 3

Acute Tox. 3

Skin Corr. 1B

Eye Dam. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H330

H311

H301

H314

H318

H317

H400

H410

GHS05

GHS06

GHS09

Dgr

H330

H311

H301

H314

H317

H410

EUH071

Skin Sens. 1A; H317: C ≥ 0,0015 %

M = 10

M = 1’

 

‘613-327-00-4

pyroxsulam (ISO);

N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide

422556-08-9

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

 

M = 100

M = 100’

 

‘613-328-00-X

1-vinylimidazole

214-012-0

1072-63-5

Repr. 1B

H360D

GHS08

Dgr

H360D

 

Repr. 1B; H360D: C ≥ 0,03 %’

 

‘616-224-00-2

amisulbrom (ISO);

3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide

348635-87-0

Carc. 2

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H319

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H319

H410

 

M = 10

M = 10’

 


Top